RA CAPITAL MANAGEMENT, LLC
13F Reported Value
ⓘ$11.5B
Holdings
84
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
RA CAPITAL MANAGEMENT, LLC disclosed 84 positions worth $11.5B in its Form 13F-HR for Q2 2026, led by $ASND (Ascendis Pharma A/S) at 23.8% of the equity portfolio, followed by $PBLS and $RYTM. During the quarter the fund opened 16 new positions and exited 17 — including a new stake in $PBLS and a full exit from $DNTH. The portfolio is most concentrated in Healthcare (99.5% of disclosed assets). All figures are sourced directly from RA CAPITAL MANAGEMENT, LLC’s Form 13F-HR filing with the SEC under CIK 1346824.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 44.8#1,898
Quality
$2.7B10,281,496 sh - —
Quality
$791.9M28,933,371 sh - 33.9#2,366
Quality
$740.2M6,666,837 sh - —
Quality
$667.0M11,474,599 sh - —
Quality
$435.7M9,905,045 sh - —
Quality
$389.6M12,198,625 sh - —
Quality
$341.0M8,392,730 sh - —
Quality
$323.7M9,550,191 sh - $286.8M7,808,627 sh
- 59.2
Quality
$234.3M6,995,858 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Ascendis Pharma A/S$ASND | 44.8#1,898 | $2.7B | 10,281,496 |
 Parabilis Medicines, Inc.$PBLS | — | $791.9M | 28,933,371 |
 RHYTHM PHARMACEUTICALS, INC.$RYTM | 33.9#2,366 | $740.2M | 6,666,837 |
 Vaxcyte, Inc.$PCVX | — | $667.0M | 11,474,599 |
 Sionna Therapeutics, Inc.$SION | — | $435.7M | 9,905,045 |
 Tyra Biosciences, Inc.$TYRA | — | $389.6M | 12,198,625 |
 Edgewise Therapeutics, Inc.$EWTX | — | $341.0M | 8,392,730 |
 NewAmsterdam Pharma Co N.V.$NAMS | — | $323.7M | 9,550,191 |
 Hemab Therapeutics Holdings, Inc.$COAG | — | $286.8M | 7,808,627 |
 Septerna, Inc.$SEPN | 59.2 | $234.3M | 6,995,858 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of RA CAPITAL MANAGEMENT, LLC's 84 positions.
Showing top 10 of 84 holdings.
Sector Allocation
Healthcare
$11.5B
Other
$31.4M
Technology
$10.9M
Financials
$9.5M
Full Holdings — RA CAPITAL MANAGEMENT, LLC (Q2 2026)
All 84 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $ASND | Ascendis Pharma A/S | $2.7B | 23.8% | +0% | 44.8 |
| 2 | $PBLS | Parabilis Medicines, Inc. | $791.9M | 6.9% | NEW | — |
| 3 | $RYTM | RHYTHM PHARMACEUTICALS, INC. | $740.2M | 6.4% | +0% | 33.9 |
| 4 | $PCVX | Vaxcyte, Inc. | $667.0M | 5.8% | +0% | — |
| 5 | $SION | Sionna Therapeutics, Inc. | $435.7M | 3.8% | +0% | — |
| 6 | $TYRA | Tyra Biosciences, Inc. | $389.6M | 3.4% | +0% | — |
| 7 | $EWTX | Edgewise Therapeutics, Inc. | $341.0M | 3.0% | -20% | — |
| 8 | $NAMS | NewAmsterdam Pharma Co N.V. | $323.7M | 2.8% | +0% | — |
| 9 | $COAG | Hemab Therapeutics Holdings, Inc. | $286.8M | 2.5% | NEW | — |
| 10 | $SEPN | Septerna, Inc. | $234.3M | 2.0% | +0% | 59.2 |
| 11 |  $BCAX | Bicara Therapeutics Inc. | $215.4M | 1.9% | +0% | — |
| 12 |  $MLYS | Mineralys Therapeutics, Inc. | $207.6M | 1.8% | +0% | — |
| 13 |  $GHRS | GH Research PLC | $205.3M | 1.8% | -1% | — |
| 14 |  $IRON | Disc Medicine, Inc. | $179.2M | 1.6% | +0% | — |
| 15 |  $SGP | SpyGlass Pharma, Inc. | $178.6M | 1.6% | +0% | — |
| 16 |  $ARTV | Artiva Biotherapeutics, Inc. | $174.2M | 1.5% | +82% | 9.7 |
| 17 |  $JANX | Janux Therapeutics, Inc. | $171.9M | 1.5% | +0% | 30.1 |
| 18 |  $TSHA | Taysha Gene Therapies, Inc. | $160.4M | 1.4% | +0% | 4.9 |
| 19 |  $BCRX | BIOCRYST PHARMACEUTICALS INC | $158.3M | 1.4% | +0% | 53.2 |
| 20 |  $WVE | Wave Life Sciences, Inc. | $156.7M | 1.4% | +0% | 7.5 |
| 21 |  $NUVL | Nuvalent, Inc. | $153.9M | 1.3% | -51% | — |
| 22 |  $ABVX | Abivax S.A. | $150.9M | 1.3% | NEW | — |
| 23 |  $ORKA | Oruka Therapeutics, Inc. | $148.0M | 1.3% | NEW | — |
| 24 |  $CLYM | Climb Bio, Inc. | $147.4M | 1.3% | +0% | — |
| 25 |  $SLDB | Solid Biosciences Inc. | $120.2M | 1.0% | +29% | — |
| 26 |  $ZLAB | Zai Lab Ltd | $109.1M | 0.9% | +1% | — |
| 27 |  $SPRY | ARS Pharmaceuticals, Inc. | $87.0M | 0.8% | +0% | 20.3 |
| 28 |  $XNCR | Xencor Inc | $84.9M | 0.7% | +8% | 11.6 |
| 29 |  $JBIO | Jade Biosciences, Inc. | $81.6M | 0.7% | +0% | — |
| 30 |  $NTLA | Intellia Therapeutics, Inc. | $76.6M | 0.7% | NEW | 19.9 |
| 31 |  $LBRX | LB PHARMACEUTICALS INC | $71.7M | 0.6% | +0% | — |
| 32 |  $DFTX | Definium Therapeutics, Inc. | $70.6M | 0.6% | NEW | — |
| 33 |  $ACRS | Aclaris Therapeutics, Inc. | $67.3M | 0.6% | +87% | 12 |
| 34 |  $FDMT | 4D Molecular Therapeutics, Inc. | $67.2M | 0.6% | +0% | 34.5 |
| 35 |  $SANA | Sana Biotechnology, Inc. | $65.4M | 0.6% | NEW | — |
| 36 |  $DMRA | Damora Therapeutics, Inc. | $62.4M | 0.5% | +0% | — |
| 37 |  $MNPR | Monopar Therapeutics | $61.8M | 0.5% | +0% | — |
| 38 |  $ABOS | Acumen Pharmaceuticals, Inc. | $56.1M | 0.5% | +0% | — |
| 39 |  $GERN | GERON CORP | $54.8M | 0.5% | -33% | — |
| 40 |  $RZLT | Rezolute, Inc. | $49.1M | 0.4% | +3% | — |
| 41 |  $EVMN | Evommune, Inc. | $46.4M | 0.4% | +0% | 14.9 |
| 42 |  $VOR | Vor Biopharma Inc. | $44.2M | 0.4% | -56% | — |
| 43 |  $IPSC | Century Therapeutics, Inc. | $43.5M | 0.4% | +0% | 33.5 |
| 44 |  $AKTS | Aktis Oncology, Inc. | $42.4M | 0.4% | -13% | — |
| 45 |  $BIOA | BioAge Labs, Inc. | $41.0M | 0.4% | +1% | 26.8 |
| 46 |  $CCCC | C4 Therapeutics, Inc. | $37.4M | 0.3% | +0% | 18.2 |
| 47 |  $MIRM | Mirum Pharmaceuticals, Inc. | $37.3M | 0.3% | +0% | 35 |
| 48 |  $CAPR | CAPRICOR THERAPEUTICS, INC. | $36.3M | 0.3% | +0% | 13.6 |
| 49 |  $PEPG | PepGen Inc. | $36.1M | 0.3% | +0% | — |
| 50 |  $PRLD | Prelude Therapeutics Inc | $34.5M | 0.3% | NEW | 21.5 |
| 51 |  $NKTX | Nkarta, Inc. | $30.6M | 0.3% | +0% | — |
| 52 |  $FIXX | Q32 Bio Inc. | $29.7M | 0.3% | NEW | 36.4 |
| 53 |  $AVR | Anteris Technologies Global Corp. | $29.6M | 0.3% | +0% | — |
| 54 |  $EDIT | Editas Medicine, Inc. | $28.8M | 0.3% | NEW | 33.4 |
| 55 |  $OVID | Ovid Therapeutics Inc. | $28.2M | 0.3% | -2% | 26.4 |
| 56 |  $ASMB | ASSEMBLY BIOSCIENCES, INC. | $28.0M | 0.2% | +0% | 41.5 |
| 57 |  $ALXO | ALX ONCOLOGY HOLDINGS INC | $26.9M | 0.2% | +0% | — |
| 58 |  $BNTC | Benitec Biopharma Inc. | $24.8M | 0.2% | +0% | — |
| 59 |  $LENZ | LENZ Therapeutics, Inc. | $23.7M | 0.2% | +0% | 12.8 |
| 60 |  $LXEO | Lexeo Therapeutics, Inc. | $23.3M | 0.2% | +0% | — |
| 61 |  $ACRV | Acrivon Therapeutics, Inc. | $21.8M | 0.2% | +47% | — |
| 62 |  $ALT | Altimmune, Inc. | $19.8M | 0.2% | NEW | 8 |
| 63 |  $KPTI | Karyopharm Therapeutics Inc. | $18.7M | 0.2% | +0% | 15.1 |
| 64 |  $DRUG | BRIGHT MINDS BIOSCIENCES INC. | $18.6M | 0.2% | +0% | — |
| 65 |  $AVTX | Avalo Therapeutics, Inc. | $18.5M | 0.2% | +51% | 11.7 |
| 66 |  $OKUR | OnKure Therapeutics, Inc. | $18.2M | 0.2% | +0% | — |
| 67 | — | FAETH THERAPEUTICS INC - Common Stock | $18.1M | 0.2% | NEW | — |
| 68 |  $AURA | Aura Biosciences, Inc. | $17.8M | 0.1% | NEW | — |
| 69 |  $SABS | SAB Biotherapeutics, Inc. | $17.2M | 0.1% | +0% | — |
| 70 |  $SPTX | Seaport Therapeutics, Inc. | $15.2M | 0.1% | NEW | — |
| 71 |  $PALI | PALISADE BIO, INC. | $14.9M | 0.1% | +0% | — |
| 72 | — | HELIX ACQUISITION CORP-CL A - Common Stock | $13.3M | 0.1% | +0% | — |
| 73 |  $WAY | Waystar Holding Corp. | $10.9M | 0.1% | +0% | 65.5 |
| 74 |  $EQ | Equillium, Inc. | $9.9M | 0.1% | +0% | 11.7 |
| 75 |  $MGNX | MACROGENICS INC | $8.6M | 0.1% | +0% | 39.6 |
| 76 |  $FRNM | Freenome, Inc. | $8.2M | 0.1% | +0% | — |
| 77 |  $ACET | Adicet Bio, Inc. | $8.1M | 0.1% | -21% | — |
| 78 | $NAMS | NewAmsterdam Pharma Co N.V. | $7.1M | 0.1% | +0% | — |
| 79 |  $CRVS | Corvus Pharmaceuticals, Inc. | $6.7M | 0.1% | +0% | — |
| 80 |  $RANI | Rani Therapeutics Holdings, Inc. | $6.5M | 0.1% | +0% | — |
| 81 |  $JATT | JATT II Acquisition Corp. | $5.7M | 0.1% | NEW | — |
| 82 |  $AMAN | Amanat Acquisition Corp. | $3.8M | 0.0% | NEW | — |
| 83 |  $HOWL | Werewolf Therapeutics, Inc. | $859,349 | 0.0% | -64% | — |
| 84 |  $PTN | PALATIN TECHNOLOGIES INC | $670,318 | 0.0% | -11% | — |
New Positions (16)
$PBLS Parabilis Medicines, Inc.$791.9M$COAG Hemab Therapeutics Holdings, Inc.$286.8M$ABVX Abivax S.A.$150.9M$ORKA Oruka Therapeutics, Inc.$148.0M$NTLA Intellia Therapeutics, Inc.$76.6M$DFTX Definium Therapeutics, Inc.$70.6M$SANA Sana Biotechnology, Inc.$65.4M$PRLD Prelude Therapeutics Inc$34.5M$FIXX Q32 Bio Inc.$29.7M$EDIT Editas Medicine, Inc.$28.8M$ALT Altimmune, Inc.$19.8M$AURA Aura Biosciences, Inc.$17.8M$SPTX Seaport Therapeutics, Inc.$15.2M$JATT JATT II Acquisition Corp.$5.7MExited Positions (17)
$DNTH Dianthus Therapeutics, Inc. /DE/
$PRAX Praxis Precision Medicines, Inc.
$SRPT Sarepta Therapeutics, Inc.
$SYRE Spyre Therapeutics, Inc.
$FULC Fulcrum Therapeutics, Inc.
$OLMA Olema Pharmaceuticals, Inc.
$DSGN Design Therapeutics, Inc.
$TVTX Travere Therapeutics, Inc.
$GRAL GRAIL, Inc.
$RLMD RELMADA THERAPEUTICS, INC.
$STRO SUTRO BIOPHARMA, INC.
$CTNM Contineum Therapeutics, Inc.
$INSP Inspire Medical Systems, Inc.
$HNGE Hinge Health, Inc.
$WGS GeneDx Holdings Corp.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for RA CAPITAL MANAGEMENT, LLC including:
Track RA CAPITAL MANAGEMENT, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for RA CAPITAL MANAGEMENT, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: RA CAPITAL MANAGEMENT, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For RA CAPITAL MANAGEMENT, LLC (SEC CIK: 1346824), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in RA CAPITAL MANAGEMENT, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.